The Pharma Letter20m
BridgeBio’s Attruby wins FDA approval
The US Food and Drug Administration (FDA) on Friday approved Attruby (acoramidis), an orally-administered near-complete (≥90% ...
pharmaphorum1h
Makary confirmed as Trump's FDA pick, with Weldon for CDC
Rumours that Donald Trump had chosen Martin Makary as FDA Commissioner have been confirmed, while the President-elect has ...
FDA approves BridgeBio’s Attruby for ATTR-CM treatment
The US Food and Drug Administration (FDA) has approved BridgeBio Pharma’s Attruby (acoramidis), an oral transthyretin (TTR) ...
pharmaphorum2h
BridgeBio poised to challenge Pfizer after Attruby approval
The price is close to the average $225,000 annual cost of Pfizer's drugs, before any discounts or rebates, although BridgeBio ...
BioSpace5h
FDA Action Alert: Applied Therapeutics Awaits Verdict on Rare Disease Therapy
With two decisions originally scheduled for this week already announced, including BridgeBio's approval in ATTR-CM, the ...
devdiscourse5h
BridgeBio's Breakthrough in Rare Heart Condition Treatment
The U.S. FDA has approved Attruby, a new drug by BridgeBio, for treating a rare heart condition, redefining a market led by ...
BridgeBio: Next Chapter Begins After Attruby Approval
2025 will be a very eventful year for BridgeBio. In addition to the commercial launches of Attruby in the United States, ...
BridgeBio Pharma : FDA Approves Heart Disease Drug 'acoramidis'
BridgeBio Pharma Inc. (BBIO) announced that the U.S. Food and Drug Administration approved Attruby or acoramidis, an ...
devdiscourse1d
Revolutionary Drug Approvals and Global Health Updates
The latest health news highlights BridgeBio's new heart drug approved by the FDA, novel findings in breast cell research, ...
BioSpace1d
BridgeBio Wins FDA Approval for ATTR-CM Drug, Launching Competition With Pfizer
BridgeBio secured approval for Attruby Friday, along with the all-important mortality benefit that could give the drug a ...
Pfizer meets amyloidosis rival as BridgeBio wins FDA nod for Attruby
BridgeBio Pharma (BBIO) wins FDA nod Attruby for rare heart disorder, ATTR-CM challenging Pfizer's (PFE) Vyndaqel. Read more ...
US FDA approves BridgeBio's drug for rare heart condition
The U.S. Food and Drug Administration has approved BridgeBio's drug for a rare and deadly heart condition, the company said ...